ProQR Therapeutics NV (PRQR)
1.63
-0.02
(-1.21%)
USD |
NASDAQ |
Oct 07, 11:26
ProQR Therapeutics Enterprise Value : 114.03M for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 114.03M |
| October 05, 2026 | 116.85M |
| October 02, 2026 | 111.91M |
| October 01, 2026 | 111.20M |
| September 30, 2026 | 115.44M |
| September 29, 2026 | 114.03M |
| September 28, 2026 | 114.03M |
| September 25, 2026 | 114.03M |
| September 24, 2026 | 122.49M |
| September 23, 2026 | 121.08M |
| September 22, 2026 | 149.31M |
| September 21, 2026 | 143.66M |
| September 18, 2026 | 139.43M |
| September 17, 2026 | 147.90M |
| September 16, 2026 | 143.66M |
| September 15, 2026 | 140.84M |
| September 14, 2026 | 143.66M |
| September 11, 2026 | 143.66M |
| September 10, 2026 | 154.95M |
| September 09, 2026 | 162.01M |
| September 08, 2026 | 170.47M |
| September 04, 2026 | 173.30M |
| September 03, 2026 | 176.12M |
| September 02, 2026 | 184.59M |
| September 01, 2026 | 180.35M |
| Date | Value |
|---|---|
| August 31, 2026 | 181.76M |
| August 28, 2026 | 204.34M |
| August 27, 2026 | 208.58M |
| August 26, 2026 | 212.81M |
| August 25, 2026 | 217.04M |
| August 24, 2026 | 224.10M |
| August 21, 2026 | 211.40M |
| August 20, 2026 | 201.52M |
| August 19, 2026 | 194.47M |
| August 18, 2026 | 184.59M |
| August 17, 2026 | 153.54M |
| August 14, 2026 | 152.13M |
| August 13, 2026 | 142.25M |
| August 12, 2026 | 143.66M |
| August 11, 2026 | 152.13M |
| August 10, 2026 | 136.61M |
| August 07, 2026 | 145.78M |
| August 06, 2026 | 149.31M |
| August 05, 2026 | 159.19M |
| August 04, 2026 | 139.43M |
| August 03, 2026 | 122.49M |
| July 31, 2026 | 123.90M |
| July 30, 2026 | 132.37M |
| July 29, 2026 | 125.32M |
| July 28, 2026 | 129.55M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pharming Group NV | 653.60M |
| NewAmsterdam Pharma Co. NV | 1.985B |
| argenx SE | 57.52B |
| Mirum Pharmaceuticals, Inc. | 5.456B |
| ACADIA Pharmaceuticals, Inc. | 2.515B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.15M |
| Revenue (Quarterly) | 10.18M |
| Total Expenses (Quarterly) | 20.33M |
| EPS Diluted (Quarterly) | -0.0923 |
| Gross Profit Margin (Quarterly) | 91.93% |
| Profit Margin (Quarterly) | -99.65% |
| Earnings Yield | -28.45% |
| Normalized Earnings Yield | -28.49 |